Form 4: Royalty Pharma EVP Acquires Shares via Equity Awards

Royalty Pharma plc's EVP, Investments & CLO, George W. Lloyd, acquired 3,696 Class A Ordinary Shares through the settlement of equity performance awards and was granted additional derivative interests.

Summary

• George W. Lloyd, EVP, Investments & CLO of Royalty Pharma plc (RPRX), acquired 3,696 Class A Ordinary Shares on August 6, 2025.
• This acquisition was exempt under Rule 16b-3 and resulted from the settlement of Equity Performance Awards, with a price of $0 per share.
• Lloyd also received a grant of 8,500 LP interests in RPI US Partners 2019, LP on August 8, 2025.
• Each LP interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited, which then convert to one Class A Ordinary Share of Royalty Pharma plc, effectively representing 85,000 underlying Class A Ordinary Shares from this new grant.
• No additional value is paid by the reporting person for these exchanges.
• Following these transactions, Lloyd's total beneficial ownership includes 3,000 direct Class A Ordinary Shares and 854,173.19 indirect Class A Ordinary Shares through various entities (GWL 2023 G HoldCo LLC, IRA, GWL 2013 NG, LLC, GWL 2014 G, LLC, GWL 2020 G, LLC, GWL 2021 G, LLC) and a spouse.
• Derivative beneficial ownership includes 85,000 underlying Class A Ordinary Shares from the new grant, plus 752,732 underlying Class A Ordinary Shares from existing LP interests held indirectly through GWL 2013 NG, LLC, GWL 2014 G, LLC, GWL 2020 G, LLC, and GWL 2021 G LLC.

Sentiment

Score: 7

Explanation: The filing indicates an executive's acquisition of shares through compensation, which is generally a positive sign of alignment with shareholder interests and confidence in the company, though it's a routine compensation event rather than a discretionary purchase.

Positives

• The acquisition of shares by an executive indicates alignment of interests with shareholders.
• The settlement of Equity Performance Awards represents executive compensation, reflecting performance.

Future Outlook

The filing does not provide forward-looking statements or guidance beyond the details of the reported transactions.

Industry Context

This Form 4 filing details an executive's equity transactions, which is a routine disclosure for publicly traded companies. It does not provide broader industry trends or competitive analysis.

Related Party Transactions

• The filing details beneficial ownership through various LLCs (e.g., GWL 2023 G HoldCo LLC, GWL 2013 NG, LLC) and a spouse, which are related party holdings, but it does not disclose new related party transactions beyond the executive's compensation.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholders due to share acquisition.
• Employees: The equity award settlement is part of executive compensation, which can be a positive signal for employee morale regarding company performance and compensation practices.

Key Dates

Recommendation

The filing details a routine executive compensation event (settlement of equity awards and grant of derivative interests) rather than a discretionary open-market purchase or sale. While it shows continued executive alignment, it does not present new fundamental information that would warrant a change in investment recommendation based solely on this Form 4.

Keywords

Royalty Pharma, RPRX, SEC Form 4, Insider Trading, Equity Awards, Executive Compensation, Share Acquisition, Derivative Securities, Beneficial Ownership